Warberg Asset Management’s Inhibikase Therapeutics IKT Stock Holding History

Warberg Asset Management’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,416	Closed	-$13K	–	284
2022 Q3	$13K	Hold	2,416	–	–	﹤0.01%	222
2022 Q2	$11K	Buy	2,416 +167	+7%	+$985	﹤0.01%	201
2022 Q1	$20K	Buy	2,249 +167	+8%	+$1.34K	﹤0.01%	184
2021 Q4	$18K	Sell	2,082 -2,251	-52%	-$24.9K	﹤0.01%	179
2021 Q3	$49K	Sell	4,333 -10,667	-71%	-$144K	0.01%	160
2021 Q2	$252K	Buy	+15,000	New	+$441K	0.05%	104

Other funds holding IKT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Warberg Asset Management's IKT Position: Q4 2022 in Review

Warberg Asset Management sold out of Inhibikase Therapeutics (IKT) in Q4 2022, closing a stake of 2,416 shares — an estimated $13K sold.

Warberg Asset Management first reported a position in IKT in Q2 2021 and held it in 6 quarters. The position peaked at $252K in Q2 2021. 19 funds tracked by Wall St. Rank hold IKT as of Q4 2022.

Warberg Asset Management reported no remaining Inhibikase Therapeutics position as of Q4 2022 after selling out during the quarter.
Warberg Asset Management sold 2,416 Inhibikase Therapeutics shares in Q4 2022, an estimated $13K.
Warberg Asset Management first reported a position in Inhibikase Therapeutics in Q2 2021 and held it in 6 quarters.
Warberg Asset Management's Inhibikase Therapeutics position peaked at $252K in Q2 2021.
19 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q4 2022.

Based on Warberg Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.